Agenus Poised for Breakthrough with Upcoming Clinical Data
AI Prediction of Agenus Inc. (AGEN)
Agenus Inc. is poised for a significant potential breakthrough with its lead assets botensilimab and balstilimab in the treatment of metastatic colorectal cancer, with upcoming clinical data presentations that could catalyze its stock price.
Agenus Inc., a clinical-stage biotechnology company, focuses on immuno-oncology treatments with its leading candidates botensilimab and balstilimab. These drugs are currently in late-stage clinical trials for metastatic colorectal cancer (mCRC), a market with significant unmet needs. The company is expected to present crucial data at the upcoming AACR 2026 event on April 21, which could substantially impact its valuation and market position. A positive outcome could validate the efficacy of its treatment regimen, potentially leading to accelerated approval and commercialization. This event serves as a critical inflection point for Agenus, offering significant upside potential for investors if the results are favorable.
AGEN Report Information
Prediction Date2026-03-25
Close @ Prediction$3.56
Mkt Cap255m
IPO DateN/a
AI-derived Information
Recent News for AGEN
- Jul 13, 2:25 pm — AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment (Stocktwits)
- Jul 13, 12:53 pm — Agenus shares surge as company secures up to $340M to advance colon cancer trial (Proactive)
- Jul 13, 8:25 am — Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN) (InvestorsHub)
- Jul 13, 8:24 am — Nasdaq falls, Dow slips as oil prices rebound on fresh US-Iran fighting (Proactive)
- Jul 13, 8:24 am — Wall Street closes lower as chip selloff and oil surge weigh on markets (Proactive)
- Jul 13, 7:46 am — Agenus surges on study pivot; Apnimed lines up an IPO (BioPharma Dive)
- Jul 13, 6:59 am — Agenus rises premarket; Micron, Western Digital slide (Investing.com)
- Jul 13, 6:00 am — Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer (Business Wire)
- Jul 6, 7:30 am — Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 (Business Wire)
- Jun 25, 7:00 am — Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 (Business Wire)
- Jun 2, 4:30 pm — Agenus Announces Virtual 2026 Annual Shareholders Meeting (Business Wire)
- May 21, 5:00 pm — Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC (Business Wire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest